NIKITA SHUKLA to Adolescent
This is a "connection" page, showing publications NIKITA SHUKLA has written about Adolescent.
Connection Strength
0.171
-
A 15-Year-Old Boy With Refractory Status Epilepticus. Semin Pediatr Neurol. 2018 07; 26:101-103.
Score: 0.035
-
Cerebellar Atrophy in Pediatric-Onset Opsoclonus-Myoclonus-Ataxia Syndrome: A Large International Cohort Study. Neurol Neuroimmunol Neuroinflamm. 2026 Sep; 13(5):e200619.
Score: 0.017
-
Phenotypic Diversity and Outcomes in Pediatric NMDA Receptor Encephalitis: A 15-Year Retrospective Study from the Largest Children's Hospital in the United States. Adv Sci (Weinh). 2026 May; 13(28):e20313.
Score: 0.016
-
Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis. Ann Neurol. 2026 03; 99(3):715-729.
Score: 0.016
-
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry. J Child Neurol. 2026 04; 41(4):545-555.
Score: 0.016
-
Limited early IVIG for the treatment of pediatric myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord. 2025 May; 97:106345.
Score: 0.015
-
Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States. Neurology. 2024 Dec 10; 103(11):e209991.
Score: 0.015
-
Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis. Mult Scler. 2024 Jul; 30(8):1056-1065.
Score: 0.014
-
Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul; 87:105647.
Score: 0.014
-
Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Pediatr Neurol. 2023 08; 145:125-131.
Score: 0.013